Fresenius has secured options on 37 biosimilars from WuXi Biologics, significantly expanding its biopharma ambitions through a development agreement. The deal comes as numerous high-selling biologics approach the end of their patent protection and biosimilars could become an important tool for health care systems to contain costs. Fresenius aims to double its biosimilar revenue to nearly €2 billion, bringing Sandoz’s league at least within sight.
3PBIOVIAN consolidates its position as a trusted partner for the development and manufacturing of complex biological products, combining scientific excellence, regulatory expertise, and strong social commitment.
Formycon AG and Zydus Lifesciences Limited today jointly announced a strategic partnership for the exclusive licensing and supply of checkpoint inhibitor FYB206, a biosimilar of Keytruda (Pembrolizumab), in the U.S. and Canada, the companies said in a statement.
Rezon Bio has launched as a European contract development and manufacturing organisation (CDMO) for biologics. The new company has been created following the demerger of Polpharma Biologics into two independent companies.
Formycon AG
Rezon Bio